With little evidence, it is still difficult to know how to screen patients for social determinants of health issues, explained Rachel Gold, PhD, MPH, investigator at the Kaiser Permanente Northwest Center for Health Research and lead research scientist at OCHIN.
With little evidence, it is still difficult to know how to screen patients for social determinants of health issues, explained Rachel Gold, PhD, MPH, investigator at the Kaiser Permanente Northwest Center for Health Research and lead research scientist at OCHIN.
Transcription:
What are the challenges of figuring out which patients to screen for social determinants of health issues and how to screen them?
The biggest challenge is that there’s no evidence right now and no one has studied or effectively proven which social determinants are the most important to screen for which patients to affect which outcomes. We know that social determinants broadly affect health, mostly its driven by poverty. We can’t necessarily intervene with poverty, so we try to intervene around housing, the way this poverty manifests in more pragmatic ways. How do we intervene with housing, food insecurity, transportation needs, or child care needs? We need to figure out which patients need to be screened. In the community health center setting, when we screen patients for social determinants needs, they all tested positive. 99% of patients reported some kind of a social need, so that’s important to understand. I think, it’s probably useful to screen most patients and to at least get some kind of a baseline established, but we really don’t have very good evidence right now on, again, which patients need to be screened for which social determinant, and because we know that there’s evidence that that’ll lead to some kind of an approved outcome. So, I think the biggest challenge right now is we’re trying to figure out who to screen for what, and we don’t have evidence to support that decision-making.
There’s a lot of interest in looking at community level social determinants, and how those have effect on health. That’s the same idea. Could we use some information about a patient’s community to identify which patients should have the screening for their personal needs, or not? That might work, but, again, there hasn’t been enough patient-reported social needs documented in data sets that we can work with to do the analyses to figure out what’s effective. So, that’s probably why my interest has been on, first, figuring out how we can document this data and start collecting this data on patients. We’re not sure if it is more effective to screen for housing, food, or whatever for which patients, and we’re casting a broad net right now. But, I’m really hoping we’re going to be able to, as a scientific community and a public health community, narrow down onto the factors that are most important.
There’s another part of this question, which is, what are you going to do with the data? What do you need it for? Is it that you want to make a referral to a community resource? Is it that you want to just know what’s going on, so that your care plan can be changed? Is it that you want to be collecting data for a policy reason? If you’re the medical director of a community clinic, you can then go to your legislators and say, “hey, half of our patients are coming in with food insecurity, but there aren’t enough food resources in the community.” It depends on what you want to use the data for. So, there’s a ton of decisions that we need to make that we don’t have evidence yet to base those decisions on, and that’s, I think, the biggest challenge we’re facing now.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
2 Commerce Drive
Cranbury, NJ 08512